Ibrutinib treatment improves T cell number and function in CLL patients

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS. Peripheral...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Long, Meixiao, Beckwith, Kyle, Do, Priscilla, Mundy, Bethany L., Gordon, Amber, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey A., Flynn, Joseph M., Andritsos, Leslie A., Awan, Farrukh, Fraietta, Joseph A., June, Carl H., Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2017
Assuntos:
Clinical Medicine
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531425/
https://ncbi.nlm.nih.gov/pubmed/28714866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89756
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados